Ventyx Biosciences, Inc. (VTYX)
- Previous Close
4.2400 - Open
4.1500 - Bid 3.9700 x 200
- Ask 4.0600 x 100
- Day's Range
3.9400 - 4.1500 - 52 Week Range
1.8650 - 40.5800 - Volume
239,916 - Avg. Volume
4,024,772 - Market Cap (intraday)
282.702M - Beta (5Y Monthly) 0.27
- PE Ratio (TTM)
-- - EPS (TTM)
-3.3000 - Earnings Date Mar 25, 2024 - Mar 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.80
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.
ventyxbio.comRecent News: VTYX
Performance Overview: VTYX
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VTYX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VTYX
Valuation Measures
Market Cap
298.92M
Enterprise Value
59.20M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.23
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.29
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-40.06%
Return on Equity (ttm)
-64.56%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-192.96M
Diluted EPS (ttm)
-3.3000
Balance Sheet and Cash Flow
Total Cash (mrq)
252.22M
Total Debt/Equity (mrq)
5.13%
Levered Free Cash Flow (ttm)
-95.04M
Research Analysis: VTYX
Company Insights: VTYX
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: VTYX
Daily – Vickers Top Buyers & Sellers for 07/12/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 12/27/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 12/07/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.